Drug intelligence / Profile preview

non-nucleoside reverse transcriptase inhibitor + protease inhibitor + integrase strand transfer inhibitor

Development stage
Unknown
Lead developer
ViiV Healthcare
Modality
Small Molecules
Administration
Oral
01

Overview

This refers to a combination regimen containing three classes of antiretroviral drugs used in the treatment of HIV infection: - Non-nucleoside reverse transcriptase inhibitors (NNRTIs) inhibit HIV-1 reverse transcriptase by binding to an allosteric site, preventing viral RNA from being transcribed into DNA. - Protease inhibitors (PIs) block the activity of HIV protease, an enzyme necessary for the maturation of infectious viral particles. - Integrase strand transfer inhibitors (INSTIs) prevent integration of viral DNA into the host genome by inhibiting the integrase enzyme. Such a combination is not available as a single fixed-dose tablet or branded product but may be prescribed as part of individualized regimens for patients with resistant virus or special clinical circumstances. Each component targets a different stage in the HIV replication cycle, providing potent suppression and reducing risk of resistance development[2][3][7].

02

Targets

Integrase allosteric pocket (HIV)PR (Progesterone receptor)Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on non-nucleoside reverse transcriptase inhibitor + protease inhibitor + integrase strand transfer inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on non-nucleoside reverse transcriptase inhibitor + protease inhibitor + integrase strand transfer inhibitor.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call